Enanta Pharmaceuticals (ENTA) Capital Expenditures (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 14 years of Capital Expenditures data on file, last reported at -$11.4 million in Q3 2025.

• Quarterly Capital Expenditures fell 281.7% year-over-year to -$11.4 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$11.3 million (down 180.09% YoY) and the FY2024 annual result came in at $5.6 million, up 5130.84% from the prior year.
• Capital Expenditures fell to -$11.4 million in Q3 2025, from $155000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $8.9 million in Q1 2025 to a low of -$11.4 million in Q3 2025.
• A 5-year average of $424500.0 and a median of $196500.0 in 2022 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 9480.0% in 2023, down 542.67% in 2023.
• Tracing ENTA's Capital Expenditures over 5 years: stood at $46000.0 in 2021, then slumped by 89.13% to $5000.0 in 2022, then jumped by 9480.0% to $479000.0 in 2023, then jumped by 406.68% to $2.4 million in 2024, then tumbled by 571.28% to -$11.4 million in 2025.
• The last three Capital Expenditures figures came in at -$11.4 million (Q3 2025), $155000.0 (Q2 2025), and $8.9 million (Q1 2025), per Business Quant data.